{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:28:16Z","timestamp":1774366096010,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.clinthera.2006.09.017","type":"journal-article","created":{"date-parts":[[2006,10,24]],"date-time":"2006-10-24T17:57:34Z","timestamp":1161712654000},"page":"1247-1272","source":"Crossref","is-referenced-by-count":46,"title":["Solifenacin succinate for the treatment of symptoms of overactive bladder"],"prefix":"10.1016","volume":"28","author":[{"given":"Maria","family":"Maniscalco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devada","family":"Singh-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Wolowich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Torres-Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.09.017_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"issue":"Suppl 5A","key":"10.1016\/j.clinthera.2006.09.017_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.09.017_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","article-title":"Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review","volume":"326","author":"Herbison","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.09.017_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib5","series-title":"Ditropan [package insert]","year":"1975"},{"key":"10.1016\/j.clinthera.2006.09.017_bib6","series-title":"Ditropan XL [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.09.017_bib7","series-title":"Oxytrol [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib8","series-title":"Detrol [package insert]","year":"1998"},{"key":"10.1016\/j.clinthera.2006.09.017_bib9","series-title":"Detrol LA [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.09.017_bib10","series-title":"Sanctura [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.09.017_bib11","series-title":"Enablex [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.09.017_bib12","series-title":"VESIcare [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.09.017_bib13","series-title":"Anatomy and Physiology","author":"Shah","year":"2001"},{"key":"10.1016\/j.clinthera.2006.09.017_bib14","series-title":"Principles of Pharmacology The Pathophysiologic Basis of Drug Therapy","year":"2005"},{"key":"10.1016\/j.clinthera.2006.09.017_bib15","series-title":"The Pharmacological Basis of Therapeutics","first-page":"66","article-title":"Drugs acting at synaptic and neuroeffectorjunctional sites","author":"Weiner","year":"1985"},{"issue":"Suppl 6A","key":"10.1016\/j.clinthera.2006.09.017_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurologic basis for the overactive bladder","volume":"50","author":"de Groat","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.09.017_bib17","series-title":"Textbook of Medical Physiology","author":"Guyton","year":"1996"},{"key":"10.1016\/j.clinthera.2006.09.017_bib18","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"1533","article-title":"Management of benign prostatic hyperplasia","author":"Lee","year":"2002"},{"key":"10.1016\/j.clinthera.2006.09.017_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.09.017_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1464-410X.2003.04609.x","article-title":"The prevalence of urinary incontinence in women in four European countries","volume":"93","author":"Hunskaar","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.09.017_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.urology.2003.10.037","article-title":"Costs of urinary incontinence and overactive bladder in the United States: A comparative study","volume":"63","author":"Hu","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2006.09.017_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11934-003-0021-3","article-title":"Muscarinic receptors: What we know","volume":"4","author":"Scarpero","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clinthera.2006.09.017_bib24","series-title":"Poster presented at: 32nd Annual General Meeting of the International Continence Society","article-title":"YM905 is effective and safe as treatment of overactive bladder in women and men: Results from Phase II study","author":"Smith","year":"2002"},{"key":"10.1016\/j.clinthera.2006.09.017_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-410X.2004.05255.x","article-title":"Improved quality of life in patients with overactive bladder symptoms treated with solifenacin","volume":"95","author":"Kelleher","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.09.017_bib26","first-page":"696","article-title":"Pharmacokinetics, metabolism, and saliva output during trans dermal and extended-release oral oxybutynin administration in healthy subjects","volume":"78","author":"Appell","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib27","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2165\/00003495-200464150-00003","article-title":"Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations","volume":"64","author":"Hashim","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.09.017_bib28","first-page":"687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial","volume":"78","author":"Diokno","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-5347(05)00017-0","article-title":"Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder","volume":"175","author":"Maruyama","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib30","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized, controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejphar.2004.03.044","article-title":"In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats","volume":"492","author":"Ohtake","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0706560","article-title":"Muscarinic receptors in the bladder: From basic research to therapeutics","volume":"147","author":"Hegde","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","article-title":"M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland","volume":"366","author":"Ikeda","year":"2002","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib34","series-title":"Poster presented at: 33rd Annual General Meeting of the International Continence Society","article-title":"Pharmacological effects of solifenacin (YM905) on human iso lated urinary bladder","author":"Masumaga","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib35","series-title":"Physicochemical properties of solifenacin succinate","year":"2006"},{"key":"10.1016\/j.clinthera.2006.09.017_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00126839-200405020-00002","article-title":"Solifenacin demonstrates high absolute bioavailability in healthy men","volume":"5","author":"Kuipers","year":"2004","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2006.09.017_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2004.02097.x","article-title":"Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: Results of a randomized crossover trial","volume":"58","author":"Uchida","year":"2004","journal-title":"BrJ Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1177\/0091270004267592","article-title":"Pharmacokinetics and safety of solifenacin succinate in healthy young men","volume":"44","author":"Smulders","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib39","series-title":"Poster presented at: 32nd Annual General Meeting of the International Continence Society","article-title":"Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905","author":"Smith","year":"2002"},{"key":"10.1016\/j.clinthera.2006.09.017_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5414\/CPP43227","article-title":"Effect of age on the pharmacokinetics of solifenacin in men and women","volume":"43","author":"Krauwinkel","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.09.017_bib41","series-title":"Poster presented at: 33rd Annual General Meeting of the International Continence Society","article-title":"The safety, tolerability, and pharmacokinetics of solifenacin succi nate in patients with hepatic impairment","author":"Kuipers","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib42","series-title":"Poster presented at: 33rd Annual General Meeting of the International Continence Society","article-title":"The safety, tolerability and pharmacokinetics of solifenacin succinate in patients with mild, moderate, and severe renal disease","author":"Smulders","year":"2003"},{"key":"10.1016\/j.clinthera.2006.09.017_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02353864","article-title":"Comparison of the Akaike Information Criterion, the Schwarz Criterion and the F test as guides to model selection","volume":"22","author":"Ludden","year":"1994","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2006.09.017_bib44","first-page":"128","article-title":"Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: Implications for binding of drugs","volume":"30","author":"Viani","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib45","series-title":"Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring","first-page":"82","article-title":"Influence of protein binding and use of unbound (free) drug concentrations","author":"MacKichan","year":"2006"},{"key":"10.1016\/j.clinthera.2006.09.017_bib46","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"33","article-title":"Clinical pharmacokinetics and pharmacodynamics","author":"Bauer","year":"2002"},{"key":"10.1016\/j.clinthera.2006.09.017_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01059688","article-title":"Hepatic clearance of drugs. I. Theoretical considerations of a \"well-stirred\" model and a \u201cparallel tube\u201d model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance","volume":"5","author":"Pang","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2006.09.017_bib48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1015961424122","article-title":"Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery","volume":"6","author":"Meijer","year":"1989","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2006.09.017_bib49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1081\/DMR-120000654","article-title":"Mechanisms and clinical implications of renal drug excretion","volume":"33","author":"Masereeuw","year":"2001","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2006.09.017_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by thera peutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2006.09.017_bib51","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.clinthera.2005.09.002","article-title":"Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: A double-blind, placebo-controlled study","volume":"27","author":"Taekema-Roelvink","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.09.017_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symp tomatic idiopathic detrusor overactivity in a placebo- and tolterodinecontrolled phase 2 dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.09.017_bib53","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, doubleblind placebo- and tolterodine controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2006.09.017_bib55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1185\/030079905X74907","article-title":"Efficacy of solifenacin in patients with severe symptoms of overactive bladder: A pooled analysis","volume":"22","author":"Millard","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2006.09.017_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.eururo.2005.09.014","volume":"49","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00002512-200118070-00007","article-title":"Twelve-month treatment of overactive bladder: Efficacy and tolerability of tolterodine","volume":"18","author":"Abrams","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2006.09.017_bib60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0302-2838(03)00054-X","article-title":"European psychometric validation of the CONTILIFE: A quality of life questionnaire for urinary incontinence","volume":"43","author":"Amarenco","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2006.09.017_bib61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1098-3015(10)61186-2","article-title":"Validation of the perception of bladder condition measure in overactive bladder","volume":"5","author":"Coyne","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2006.09.017_bib62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1023422208910","article-title":"Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder","volume":"12","author":"Reese","year":"2003","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2006.09.017_bib63","unstructured":"http:\/\/www.amerisourebergen.com. Accessed January 7, 2006."},{"key":"10.1016\/j.clinthera.2006.09.017_bib64","unstructured":"http:\/\/\/www.mckesson.com. Accessed January 7, 2006."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:07:33Z","timestamp":1587236853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806002244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0149291806002244"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.09.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}